News
-
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Xenetic Biosciences to present abstract at SITC 39th Annual Meeting on DNase I targeting Neutrophil Extracellular Traps for improved immune checkpoint blockade in CRC models -
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic partners with Tokyo Medical University to evaluate recombinant DNase I for Ewing sarcoma treatment in preclinical model. Agreement enhances DNase program development -
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Xenetic Biosciences presented at H.C. Wainwright 26th Annual Global Investment Conference. The biopharmaceutical company focuses on immune-oncology technologies for hard-to-treat cancers -
